CPI(M) State secretary M.V. Govindan accused the Kerala UDF government of failing to protect children with spinal muscular atrophy (SMA). He claims the administration is following a privatisation agenda that undermines public health systems and infrastructure funds.
Simple details
- CPI(M) State secretary M.V. Govindan led the criticism
- Health Minister K. Muraleedharan is the target of the queries
- Drugs meant for clinical trials were administered to SMA patients
- KIIFB spent ₹6,670 crore in the health sector
- 579 school buildings were constructed via KIIFB funds
- The CPI(M) alleges the UDF is following a privatisation agenda
Political clash over SMA treatment
CPI(M) State secretary M.V. Govindan held a press conference on Friday. This followed the CPI(M) State committee meeting.
He questioned the Health Minister over drug administration for SMA patients. The party leader stated that parents were not given convincing answers.
They were unsure why drugs meant for clinical trials were used. Mr. Govindan rejected the Health Minister’s claim that the previous LDF government made these decisions.
Impact on public health trust
This controversy affects families of children suffering from spinal muscular atrophy in Kerala. These parents are now questioning the safety protocols followed by state hospitals.
They are concerned that research drugs were used in treatment without proper disclosure. The CPI(M) argues that this incident is part of a broader pattern.
- Parents of SMA-afflicted children who received trial drugs
- Patients relying on public hospitals for critical care
- Advocates for generic medicines and public health infrastructure
- Citizens concerned about the role of KIIFB in development
- Voters watching the UDF government’s policy direction
They believe the government is shifting health services toward private entities. This shift could reduce the accessibility of affordable treatments for common citizens.
Background on the dispute
The CPI(M) has a long history of supporting generic medicines and public health systems. They view the current actions as a departure from this legacy.
The party alleges that the UDF government is implementing policies similar to the BJP’s corporate Hindutva agenda. Mr. Govindan cited specific financial figures to support his claims.
He noted that development works worth ₹1 lakh crore were taken up under KIIFB. In the health sector, an amount of ₹6,670 crore was spent.
Additionally, projects worth over ₹25,000 crore were undertaken under the PWD. He also mentioned that ₹5,580 crore from KIIFB helped make the national highway a reality.
As many as 579 school buildings were constructed using these funds. Hill and coastal highways were also built through this mechanism.
He alleged that central agencies have long tried to destroy KIIFB to hinder Kerala’s development. The CPI(M) claims the UDF is now implementing this aim.
Reality check
This explainer relies on statements made by the CPI(M) State secretary. It does not confirm the medical safety of the drugs used.
The Health Minister has not yet responded to these specific queries in the source text. Readers should verify medical advice from qualified professionals.
The financial figures cited are claims by the opposition party. They have not been independently audited in this report.
The political context involves allegations of motive, which are subjective. Facts regarding the drug administration are based on the party’s statements.
Who should buy and who should skip
- Readers interested in Kerala state politics and healthcare policy
- Parents of children with rare diseases in public hospitals
- Analysts tracking the UDF government’s infrastructure decisions
- Readers seeking verified medical advice on SMA treatments
- Those looking for non-partisan financial audits of KIIFB
- Individuals uninterested in political party rhetoric
Verdict
This story highlights a significant political dispute over healthcare transparency in Kerala. It is essential for understanding the current tensions between the UDF and CPI(M).
Readers should monitor official responses from the Health Minister for further clarity. The situation may lead to further political escalation.
What happens next
The Health Minister is expected to respond to the six pointed queries. These questions include how trial drugs ended up in hospitals.
There is also a query about whether bioequivalence studies were conducted. Both parties are likely to use this issue to rally their supporters.
- Official response from Health Minister K. Muraleedharan regarding drug safety
- Investigation into the relaxation of tender clauses for specific companies
- Clarification on the responsibility for any side effects in children
- Political debate on the future of KIIFB and its funds
- Potential legal or administrative review of hospital drug protocols
The focus will remain on the transparency of the drug supply chain. The situation may lead to further political escalation in the state assembly.
Read the news report this explainer is based on: CPI(M) turns the heat on Keralam govt. over SMA drug controversy.
Source: Ebenezer News Explainer Desk · Ebenezer News Explainer Desk. Published 23 Oct 2026, 04:24 pm.
